Amina Essalihi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amina Essalihi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Khadija Khadiri
Laboratory of Immunology and Biodiversity, Faculty of Sciences, Aïn Chock, Hassan II University of Casablanca, Casablanca, Morocco
3 shared publicationsMehdi Karkouri
Laboratory of Cellular and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco
3 shared publicationsOumaima Bouchra
Laboratory of Cellular and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco
3 shared publicationsZineb Khadrouf
Laboratory of Immunology and Biodiversity, Faculty of Sciences, Aïn Chock, Hassan II University of Casablanca, Casablanca, Morocco
3 shared publicationsAbdellah Idrissi Azami
Mohammed VI University of Sciences and Health
2 shared publicationsHassan Ghazal
Mohammed VI University of Sciences and Health
2 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- Vol. 13 (3) , 348-358
Immunogenomic Characterization of Triple-Negative Breast Cancer in a Moroccan Cohort and Its Prognostic Implication
Background: In North Africa, triple-negative breast cancer (TNBC) is a highly prevalent, aggressive, and diverse disease with unique clinical features. In this population, the prognostic significance of immune infiltration and genomic changes is still not fully understood. In order to investigate their relationships with relapse-free survival, this study sought to provide an integrated analysis of the tumor immune microenvironment and BRCA1 and BRCA2 variant landscape in Moroccan TNBC patients. Methods: A retrospective cohort of Moroccan TNBC patients was evaluated using immunohistochemistry (IHC) to assess stromal tumor-infiltrating lymphocytes (TILs), programmed death-ligand 1 (PD-L1) expression, and immune cell subsets (CD3, CD4, CD20, and CD56). Targeted next-generation sequencing of BRCA1 and BRCA2 was performed on tumor tissue. Associations between immune biomarkers, genomic variants, and clinical outcomes were analyzed using appropriate statistical and bioinformatic approaches. Results: The cohort exhibited significant heterogeneity in immune infiltration and advanced disease at diagnosis. Higher stromal TIL levels were observed in patients without relapse, although this association did not reach statistical significance in the present cohort. BRCA1 and BRCA2 variants were frequently detected and showed heterogeneous immune profiles across tumors. Limited redundancy among immune markers was found in correlation analyses, suggesting that these markers may capture complementary aspects of the immune microenvironment. Conclusion: This integrated immunogenomic analysis suggests the potential prognostic relevance of the tumor immune microenvironment in Moroccan TNBC patients. The findings emphasize the value of multiparametric immune and genomic profiling for improved risk stratification and support further investigation of population-specific immunogenomic patterns in North African TNBC patients.
- 25 July 2026
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- Vol. 13 (3) , 348-358
Open AccessImmunogenomic Characterization of Triple-Negative Breast Cancer in a Moroccan Cohort and Its Prognostic Implication
Background: In North Africa, triple-negative breast cancer (TNBC) is a highly prevalent, aggressive, and diverse disease with unique clinical features. In this population, the prognostic significance of immune infiltration and genomic changes is still not fully understood. In order to investigate their relationships with relapse-free survival, this study sought to provide an integrated analysis of the tumor immune microenvironment and BRCA1 and BRCA2 variant landscape in Moroccan TNBC patients. Methods: A retrospective cohort of Moroccan TNBC patients was evaluated using immunohistochemistry (IHC) to assess stromal tumor-infiltrating lymphocytes (TILs), programmed death-ligand 1 (PD-L1) expression, and immune cell subsets (CD3, CD4, CD20, and CD56). Targeted next-generation sequencing of BRCA1 and BRCA2 was performed on tumor tissue. Associations between immune biomarkers, genomic variants, and clinical outcomes were analyzed using appropriate statistical and bioinformatic approaches. Results: The cohort exhibited significant heterogeneity in immune infiltration and advanced disease at diagnosis. Higher stromal TIL levels were observed in patients without relapse, although this association did not reach statistical significance in the present cohort. BRCA1 and BRCA2 variants were frequently detected and showed heterogeneous immune profiles across tumors. Limited redundancy among immune markers was found in correlation analyses, suggesting that these markers may capture complementary aspects of the immune microenvironment. Conclusion: This integrated immunogenomic analysis suggests the potential prognostic relevance of the tumor immune microenvironment in Moroccan TNBC patients. The findings emphasize the value of multiparametric immune and genomic profiling for improved risk stratification and support further investigation of population-specific immunogenomic patterns in North African TNBC patients.
- Open Access
- 17 June 2025
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 37 (1) , 1-10
Immunotherapy for triple-negative breast cancer: current trends and future prospects
Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers. These tumors are heterogeneous, highly aggressive, and associated with a poor prognosis and a high risk of recurrence. In both hematologic and solid malignancies, immune checkpoint inhibitors (ICIs) have demonstrated the ability to enhance long-term survival and sustain robust anti-tumor responses. Immunotherapy has also been introduced as a treatment option for TNBC, a subtype characterized by a high presence of intra-tumoral tumor-infiltrating lymphocytes (TILs) and stromal immune cells. This heightened immune activity within TNBC serves as a prognostic marker, indicating a potential for better responses to immunotherapy due to increased tumor immune infiltration. This review provides an overview of the current landscape of immunotherapy in TNBC, exploring its rationale and application across different disease stages. Trial registration NCT02555657.
- 17 June 2025
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 37 (1) , 1-10
Open AccessImmunotherapy for triple-negative breast cancer: current trends and future prospects
Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers. These tumors are heterogeneous, highly aggressive, and associated with a poor prognosis and a high risk of recurrence. In both hematologic and solid malignancies, immune checkpoint inhibitors (ICIs) have demonstrated the ability to enhance long-term survival and sustain robust anti-tumor responses. Immunotherapy has also been introduced as a treatment option for TNBC, a subtype characterized by a high presence of intra-tumoral tumor-infiltrating lymphocytes (TILs) and stromal immune cells. This heightened immune activity within TNBC serves as a prognostic marker, indicating a potential for better responses to immunotherapy due to increased tumor immune infiltration. This review provides an overview of the current landscape of immunotherapy in TNBC, exploring its rationale and application across different disease stages. Trial registration NCT02555657.
- 10 June 2025
- Published by Springer Nature
- p. 287-294
Study of Recurrent Genetic Variants in the Moroccan Population
- 10 June 2025
- Published by Springer Nature
- p. 287-294
Study of Recurrent Genetic Variants in the Moroccan Population
- 10 June 2025
- Published by Springer Nature
- p. 317-329
Analysis of BRCA1 and BRCA2 Variants in Moroccan Patients with Triple-Negative Breast Cancer (TNBC)
- 10 June 2025
- Published by Springer Nature
- p. 317-329
Analysis of BRCA1 and BRCA2 Variants in Moroccan Patients with Triple-Negative Breast Cancer (TNBC)